Patient must consent to provision of, and Investigator(s) must confirm access to and agree to submit a representative formalin fixed paraffin block of tumor tissue in order that the specific correlative marker assays may be conducted. Submission of the tissue does not have to occur prior to randomization. Where local center regulations prohibit submission of blocks of tumor tissue, two 2 mm cores of tumor from the block and 10-30 unstained slides of whole sections of representative tumor tissue are preferred. Where two 2 mm cores of tumor from the block are unavailable, 10-30 unstained slides of whole sections of representative tumor tissue alone are acceptable. Where no previously resected or biopsied tumor tissue exists or is available, on the approval of the Sponsor/designated CRO, the patient may still be considered eligible for the study.
Patients must have adequate tumor tissue available, defined as >= 20% tumor cells and >= 0.2 mm^3 tumor volume\r\n* The local interpreting pathologist must review the specimen\r\n* The pathologist must sign the S1400 Local Pathology Review Form confirming tissue adequacy prior to screening/pre-screening registration\r\n* Patients must agree to have this tissue submitted to Foundation Medicine for common broad platform Clinical Laboratory Improvement Act (CLIA) biomarker profiling and c-MET IHC; if archival tumor material is exhausted, then a new fresh tumor biopsy that is formalin-fixed and paraffin-embedded (FFPE) must be obtained; a tumor block or FFPE slides 4-5 microns thick must be submitted; bone biopsies are not allowed; if FFPE slides are to be submitted, at least 12 unstained slides plus an H&E stained slide, or 13 unstained slides must be submitted; however it is strongly recommended that 20 FFPE slides be submitted; Note: previous next-generation deoxyribonucleic acid (DNA) sequencing (NGS) will be repeated if done outside this study for sub-study assignment; patients must agree to have any tissue that remains after NGS testing retained for the use of the translational medicine (TM) studies (if such TM studies are defined) within any sub-study the patient is enrolled in
Patients must have a minimum of five, available unstained slides from the residual (post-neoadjuvant) invasive tumor in primary site or lymph node; (these will be submitted to determine PD-L1 expression) the tumor tissue must be adequate for PD-L1 testing, which typically requires a minimum of 100 cancer cells per slide\r\n* NOTE: Initial order for specimen kits should be placed at least two weeks prior to registering the first patient at each site
Archival tumor tissue or a newly obtained biopsy must be available prior to the first dose of study drug for biomarker analysis. In the case archival tissue cannot be provided, participants with inaccessible tumors for biopsy specimens can be enrolled without a biopsy upon consultation and agreement by the sponsor Note: In case of submitting unstained cut slides, freshly cut slides should be submitted to the testing laboratory within 14 days from when the slides are cut
A representative formalin-fixed, paraffin-embedded tumor specimen in paraffin blocks, or at least 20 unstained slides with an associated pathology report documenting ER, PR, and HER2 negativity. Participants with fewer than 20 unstained slides available at baseline, and not fewer than 12 unstained slides will be eligible upon discussion with Medical Monitor
Participants must have fifteen blank (unstained) slides or a diagnostic tissue block must be available for external quality assurance by the AMC Core Pathology Laboratory
The patient must have at least 1 block of tissue or 15 unstained slides at a minimum available for central pathology review and molecular profiling of the tissue sample
Availability of tumor specimen block or 30 unstained slides from diagnosis of muscle-invasive disease. Patients with fewer than 30 slides available may be enrolled after discussion with the principal investigator.
Patients must have a tissue block (or 26 unstained slides) available with adequate tumor to perform multiplex immunohistochemistry and nucleic acids analyses (i.e. whole exome sequencing); patients with only a previous fine-needle aspirate are ineligible for enrollment
Archival tissue block or unstained slides (from primary or metastatic site) must be available, otherwise fresh tissue biopsy sample will be collected for patients with accessible tumors
Adequate archival frozen or fixed tissue available from primary or metastatic site for genotypic analysis (at least 15 unstained slides and/or tumor block)
Availability of at least 12 unstained slides from archival FFPE tumor tissue.
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: The availability of archival tissue to evaluate retrospectively the participantâ€™s retinoblastoma (Rb) status; the requirement is a minimum of 5 unstained slides with each tissue cut measuring 4 microns in width; ideally 15 slides will be requested; patients without available archival tissue may be enrolled at the discretion of the principal investigator
Participants must have archival tissue from the primary tumor or metastases available for correlative studies; either a paraffin block or twenty unstained slides are acceptable; if twenty slides are not available, a lesser amount may be acceptable after discussion with the principal investigator
Availability of a tissue block from initial breast cancer diagnosis and/or metastatic recurrence; if a tissue block is not available, 10-20 unstained slides may be provided as an alternative; if unstained slides will be provided, they should not be sent until specifically requested by the Dana-Farber Cancer Institute (DFCI) study coordinator; if archival tumor tissue is not available, a fresh biopsy may be performed
Confirmation of availability of FFPE tumor specimen with adequate tumor tissue (either one paraffin embedded tissue block OR 10 5-micron unstained slides from the block on regular (non-plus) slides and 1 hematoxylin and eosin [H&E] slide)
Only patients with available archival tumor tissue must consent to provision of, and Investigator(s) must confirm access to and agree to submit a representative formalin fixed paraffin block of tumor tissue in order that the specific correlative marker assays (Correlative Studies) of this protocol may be conducted. Submission of the tissue does not have to occur prior to randomization. Where local center regulations prohibit submission of blocks of tumor tissue, two 2 mm cores of tumor from the block and 5-20 unstained slides of whole sections of representative tumor tissue are preferred. Where it is not possible to obtain two 2 mm cores of tumor from the block, 5-20 unstained slides of representative tumor tissue are also acceptable. Where no previously resected or biopsied tumor tissue exists or is available, on the approval of the Sponsor/designated CRO, the patient may still be considered eligible for the study.
Consent to provide a formalin-fixed paraffin-embedded (FFPE) tissue block (preferred) or a minimum of 15 (20 preferred) freshly cut unstained tumor slides from the most recently collected, available tumor tissue accompanied by an associated pathology report (with tumor content information, Gleason score, and disease staging) for PTEN IHC and NGS testing and for other protocol-mandated secondary and exploratory assessments. If only 12-14 slides are available, the patient may still be eligible for the study, after discussion with and approval by the Medical Monitor. Cytologic or fine-needle aspiration samples are not acceptable. Tumor tissue from bone metastases is not acceptable
Patients must consent to the submission of FFPE blocks and/or unstained slides
Patients must have verbal or documented acknowledgement of availability of unstained slides or paraffin block tissue from archived tumor specimen; if not available the patient will undergo a fresh biopsy
INCLUSION CRITERIA FOR STRATUM C: Patients must have adequate pre-trial FFPE tumor material available and be willing to provide a blood sample for use in the genome wide sequencing studies; while tissue is required for genome-wide sequencing of tumor and germline samples, patients will be deemed eligible for the study with a minimum of approximately 10 unstained slides for the planned analysis
Archival tumor specimen: All subjects in Arm A must submit at least 5 unstained slides from a tumor specimen that harbors H3 K27M mutation. For subjects in Arm B, at least 5 unstained slides must be submitted if archival tissue is available from the DIPG. For subjects in any arm, if no archival tumor tissue is available, or if H3 K27M status of tumor is unknown, then subjects must agree to submit a post-mortem biopsy specimen.
Availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of 1 cm^2 of tumor surface area, or 20 unstained slides from the glioblastoma tissue specimen if a tumor block cannot be submitted
Archival tumor (up to 10 unstained slides) will be obtained, whenever available for additional biomarker analyses
Availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of 1 cm^2 of tumor surface area, or 20 unstained slides from the tumor tissue specimen if a tumor block cannot be submitted
Archived or freshly biopsied primary and/or bone metastatic tumor tissue available in paraffin-embedded blocks or slides that is expected to yield 9 slides
The tumor tissue (e.g. block or 15 unstained slides) must be available to be sent for immunophenotyping
Archival tumor sample available; a minimum of 10 unstained slides; no fine needle aspiration (FNAs) allowed or tumor tissue from bone
For breast cancer patients, at least 6 sections of unstained slides should be obtained; if sufficient slides or tissue is unavailable, the patient will be excluded from the trial; for colon cancer patients, confirmation of tissue availability is not required, but documentation that the block is available must be provided to confirm eligibility
Evaluable untreated tumor tissue for biomarker analysis (25 unstained slides or FFPE tissue block); subjects with < 25 slides may be enrolled after discussion with the sponsor-investigator or co-investigator; untreated tumor tissue is defined as no intervening intravesical or systemic therapy since acquisition; subjects without tissue available must be willing and safe to undergo biopsy repeat biopsy (core needle or excisional) prior to enrollment
Availability of >= 10 unstained 5 micron slides (to be provided to HTRC at the University of Chicago); patients who cannot fulfill this requirement will need to undergo a new biopsy prior to enrollment on study
A formalin-fixed paraffin embedded tumor block (preferred) or unstained slides must be available from a prior biopsy of the primary tumor or lymph node; a minimum of 8 slides must be available
Tumor block or unstained slides must be available for molecular profiling
Adequate archival tissue (10-15 slides, or 5 slides with 3 sections per slide) for biomarker analysis
Sufficient tumor tissue available from original diagnosis or subsequent biopsy for analysis of estrogen receptor and aromatase â€“ tumor block or a minimum of 5 unstained slides
Availability of archival tumor tissue for biomarkers analysis (minimum of 10 unstained slides are optional); specimen from primary site will be allowed
Tumor tissue available from original diagnosis and/or recurrence; a minimum of 1 FFPE archival tumor tissue block (preferred) or a minimum of 20 FFPE unstained slides from initial and/or most recent pre-registration biopsy or resection. It is recommended that at least 1 cm^2 of tissue composed primarily (defined as greater than 85%) of tumor is present.
Availability of an archival FFPE tumor tissue from primary tumor resection specimen (if not provided per above). If an FFPE tissue block cannot be providedas per documented regulations 15 unstained slides (10 minimum) will be acceptable
Archival tumor sample available; a minimum of 10 unstained slides; no fine needle aspiration (FNAs) allowed or tumor tissue from bone
Paired pre-treatment and post-treatment biopsies are required for all patients on Part 1 and first 15 patients in Part 2; participants must have available archival tumor tissue (at least 20 unstained slides); if archival tissue is not available or is found not to contain tumor tissue, a fresh biopsy is required; if a patient is having a tumor biopsy, less than 20 unstained slides are acceptable with approval of the principal investigator (PI); biopsies will only be performed in a given patient if they are not deemed to involve unacceptable risk based on the sites of disease and other concurrent medical conditions
Paraffin block or slides must be available
Patients must have available archived tissues of 20-30 unstained slides; if frozen tissues are available, at least 200 mg would be preferred, but not mandatory for study eligibility
Subject consents to provide at least 10 unstained tumor slides for retrospective testing of HRAS gene tumor status
Archival tumor tissue sample (i.e., representative tumor tissue specimen in paraffin block [preferred] or at least 20 unstained slides) must be requested and available prior to study entry
Mandatory submission of H&E and p16 stained slides for central review of p16 staining is required for oropharyngeal patients and H&E stained slide block (or punch biopsy of paraffin block) for PD-L1 expression analysis for all patients
MANDATORY archival tumor tissue (prior to treatment with a PD-1 or PD-L1 inhibitor) must be identified during screening and confirmation of acquisition should occur prior to registration. Archival tissue should not be shipped until registration of patient to study. Unavailability of tissue will render the subject ineligible for study. Sample requirement is FFPE block + 2 haemotoxylin and eosin (H&E) stained slides or 17 unstained slides + 1 H&E stained slide.
For stage 2 GBM participants, a block of paraffin embedded tissue or 30 unstained slides at standard 4-5 um thickness from any prior surgery demonstrating GBM pathology must be available for submission
Patients must have tissue available and must agree to submission of tissue and blood; one to two paraffin-embedded tissue blocks or 15-20 unstained slides are requested (a minimum of 12 slides is required); cytology (i.e. fine-needle aspirations, pleural effusion specimens) is acceptable if a cell block or sufficient unstained slides are available; tumor material must be reviewed by a local pathologist who must confirm that at least 100 viable tumor cells are present in the sample and sign the S1403 Pathology Review Form prior to registration; patients must also be willing to submit blood samples for correlative research at baseline, during treatment and at progression
Tumor tissue need be received by the central vendor (block or unstained slides). Note: Fine Needle Aspiration (FNA)and bone metastases samples are not acceptable for submission.
Patients must have tumor tissue from transurethral resection of the bladder tumor (TURBT) available for submission that is sufficient for COXEN testing and must agree to submission of 20 (10 micron) slides of formal-fixed paraffin embedded (FFPE) tissue, with 2 (5 micron) slides at the start and end of the 20 slides, for a total of 22 unstained slides; the diagnostic TURBT sample must have been obtained within 56 days prior to registration; all sections should be placed on \plus\ slides, as is the standard procedure in most pathology units
Patients must consent, if residual tumor is present at the time of cystectomy, to the submission of 20 (10 micron) unstained slides with 2 (5 micron) slides at the start and stop of the series (total of 22 unstained slides)
Patients must have available and be willing to submit a minimum of five unstained slides from primary, lymph node, or metastatic site to determine PD-L1 expression; the tumor tissue must be adequate for PD-L1 testing (defined as >= 100 tumor cells as confirmed by the treating institutionâ€™s local pathologist); this must be documented by having a pathologist sign the S1404 Local Pathology Review form prior to step 1 registration; the specimens may come from an archived block but must be submitted within 20 days from cutting the slides
Confirmed availability of representative tumor specimens in paraffin blocks/unstained slides
Baseline tumor tissue, either fresh (preferred) or from paraffin block/unstained slides if contemporary biopsy is unsafe or not otherwise obtainable from the primary tumor site or metastatic site to be available for use on correlative studies
Archival tumor tissue block or 15 freshly cut, unstained, serial slides available for submission, or willingness to undergo a core or excisional biopsy prior to enrollment (fine-needle aspiration, brush biopsy, and lavage samples are not acceptable). Participants with fewer than 15 slides available may be eligible for study entry following discussion with Medical Monitor
Patients must have tumor (paraffin block or slides) available for submission and be willing to submit tumor and blood samples
Representative tumor specimens in paraffin blocks (preferred) or at least 15 unstained slides, with an associated pathology report
Has sufficient archival tumor tissue (a minimum of 10 slides or tumor block) available for central retrospective testing of BAP1 status
Patients must have tumor (slides or block) available for submission for V600E BRAF testing
Paraffin-embedded tumor block(s) or 15 to 20 unstained slides available for centralized assessment of ER, PR, and HER2.
Patient must be able to provide either archival tumor samples (hematoxylin and eosin [H&E] slides and one paraffin block or 10 unstained slides) or undergo tumor biopsy
Pathology: representative urothelial carcinoma FFPE tumor specimens (tumor blocks or 30 unstained slides); patients with < 30 slides may be enrolled after discussion with the principal investigator
Tumor tissue (a minimum of 10 and up to 15 unstained slides, or paraffin block, ideally from the patient's most recent biopsy, must be available at the patient's local institution prior to the first dose of study therapy.
Archived tumor tissue (block or 15-20 unstained slides) available, or be willing to undergo an incisional or excisional lymph node biopsy of accessible adenopathy (or, in less accessible lymph nodes, 4 to 8 core biopsies).
Patients must have available an archival paraffin tumor block (from surgery on any meningioma or schwannoma) sufficient to generate at least 5 unstained slides; or, if a paraffin tumor block is unavailable, at least 5 unstained slides; Note: tumor block from the target meningioma is not required
Patients must have archival tissue from the primary tumor or metastases available for correlative studies; either a paraffin block or twenty unstained slides are acceptable; (if less than twenty unstained slides are available, the patient may be able to participate at the discretion of the investigator)
Availability of an archival FFPE tumor tissue block from primary diagnosis specimen (if available and not provided per above). If an FFPE tissue block cannot be provided, 15 unstained slides (10 minimum) will be acceptable
Have provided tissue from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion; while 20 unstained slides or a tumor block are preferred, at least 14 unstained slides are requested for analysis; principal investigator (PI) approval for a lower number of slides is acceptable
All patients must submit unstained slides of primary or recurrent tumor for translational analysis
Availability of archived tumor tissue for correlative studies (5 unstained slides)
Participates must be able to submit 20 unstained slides from the initial tissue diagnosis for confirmation of diagnosis and correlative studies
Must have tissue available from the pre-treatment diagnostic biopsy (tissue blocks if possible; if not possible, 10 unstained slides from each positive core sample for a total of 30 slides whenever possible)
Availability of >= 10 unstained 5 micron slides
At least 15 unstained slides or at least 1 tissue blocks must be collected from at least one prior surgery; frozen tissue is also requested if available
Patients must have archival tissue from the primary tumor or metastases available for correlative studies; either a paraffin block or twenty unstained slides are acceptable; if twenty slides are not available, a lesser amount may be acceptable after discussion with the principal investigator
The availability of archival tissue to evaluate retrospectively the participantâ€™s retinoblastoma protein (Rb) status as well as to perform next generation (NextGen) sequencing for tumor protein p53 (TP53) and liver kinase B1 (LKB1) status; the requirement is a minimum of 5 unstained slides with each tissue cut measuring 4 microns in width; ideally 15 slides will be requested; patients without available archival tissue may be enrolled at the discretion of the principal investigator
Patients must have a block of banked tumor tissue and/or fresh tumor tissue or at least 10 unstained slides available to be sent to the central laboratory
Patients should have tumor tissue available, and a tissue block of sufficient size to make 15 slides, which must be sent to Dana-Farber Cancer Institute (DFCI) for correlative research; if a tissue block is unavailable, sites may send one H&E stained slide and 15 unstained sections of paraffin-embedded tissue on uncharged slides; slide sections should be 4-5 microns in thickness; it is also acceptable to submit 2 cores from a block of invasive tissue using a 1.2 mm diameter coring tool; if tumor is not available, the investigator must document why tissue is not available in the patient medical record, and that efforts have been made to obtain tissue
Histologically confirmed definitive GBM or gliosarcoma by partial or complete surgical resection (i.e. not by biopsy only) within 5 weeks prior to PLX3397 administration (C1D1). Tumor must have a supratentorial component. For all patients, availability of a surgical paraffin tumor block sufficient to generate at least 20 unstained slides; or, if a paraffin tumor block is unavailable, at least 20 unstained slides.
Patients should have archival tumor tissue (either unstained slides or tumor blocks) available for retrieval
The mutational analysis (SNaPSHOT panel) requires a paraffin-embedded block or ten unstained slides from the untreated biopsy specimen obtained at the time of upper endoscopy or initial diagnostic biopsy; patients without sufficient material for SNaPSHOT will NOT be excluded from the study
Availability of a tissue block from initial breast cancer diagnosis and/or metastatic recurrence; if a tissue block is not available, 10-20 unstained slides may be provided as an alternative; if unstained slides will be provided, they should not be sent until specifically requested by the Dana-Farber Cancer Institute (DFCI) study coordinator
Availability of 10 unstained slides or paraffin-embedded tissue block from archived tumor specimen
Availability of archival diagnostic tissue (paraffin tissue block of resected tumor, core biopsy, fine needle aspirate cell block, or if block cannot be submitted 20-25 [5 micron] unstained slides cut from a block representative of tumor, is required)
For patients enrolled in Part 2 (surgical substudy), patients must be willing to undergo surgical resection and have pre-treatment archival tumor tissue (15 unstained paraffin slides) available for molecular analysis
EXPANSION COHORT ONLY: Patients must have pre-treatment archival tumor tissue; one paraffin block, frozen curls, or at least 10 freshly-prepared unstained slides from the most representative single paraffin-embedded tumor tissue block should be submitted; slides from the primary tumor are preferred; if both the primary and metastatic tumor blocks are available, at least 10 slides from each of the sites should be submitted, if possible; if tissue from the primary tumor is not available, a paraffin block or unstained slides from a metastatic site are acceptable; fine needle aspirates (FNAs) have insufficient tumor tissue and are not permitted
Patients must have tissue from the primary tumor or metastases available for correlative studies; either a paraffin block or at least 20 unstained slides are acceptable (30 unstained slides would be ideal); (if less than twenty unstained slides are available and a paraffin block is not available, the patient may be able to participate at the discretion of the investigator)
Must have undergone biopsy after development of acquired resistance to erlotinib with available archived tissue (equivalent of >= 10 unstained slides)
Additional available archival tumor tissue in the form of 15-20 unstained slides should be submitted to MSKCC for future correlative analysis, but will not be required prior registration; Note: if tissue is depleted, patient will still be eligible after discussion with the MSK principal investigator (PI)
At least 15 unstained slides or 1 tissue block (frozen or paraffin embedded) available from the most recent biopsy or surgery (archival tumor material); Exception: Arm C patients may be allowed to enroll without minimum number of requested unstained slides available, however consultation and approval by overall principal investigator (PI) is required
Must submit unstained slides from archival tumor tissue for PD-L1 and exploratory analysis; sites must verify that a tumor block is available to obtain unstained slides from prior to registration to the trial
Appropriate slides of the primary lesion will be available for future review; if available, HER2/neu positivity will be recorded
Have tissues from a biopsy, or have up to 20 unstained slides available from archived metastatic tissue block for biomarker evaluation
Cohort Expansion: Available archival tumor tissue block or 5-10 unstained, consecutive core biopsy slides from one archival tumor block that meet specific tissue requirements.
Archival tumor block (or 20 unstained slides) for biomarker testing. Patients without archived tumor block material will be allowed to participate in the study.
Patient has archival or fresh tumor tissue for the analysis of PI3K-related biomarkers. One tumor block (preferred) or a minimum of 12 unstained slides to be provided. Enrollment in the study is contingent on confirmation of an adequate amount of tumor tissue.
Sufficient tissue (block or slides) from diagnostic biopsy to undergo testing for FRa
A tumor tissue sample is provided for immunohistochemical analysis of relevant antigens, immune markers and potential prognostic factors. Preferably a paraffin block or 10-12 unstained slides will be submitted prior to study entry. Patients for whom tumor samples are unavailable or inadequate are permitted to participate in the study; however, the absence of available/adequate tumor specimen must be documented.
Subject has available and has provided consent to release to the sponsor (or designee) a tumor block with confirmed tumor content (or approximately 20 unstained charged slides [a minimum of 7 slides is mandatory]) and the corresponding pathology report
Availability of fixed tumor specimen (block or slides) for exploratory biomarker analysis. If no slides or block are available, fresh tumor biopsies should be obtained and used for these assessments
AR expression >= 5% by immunohistochemistry (IHC); in cases where multiple blocks are available staining will be performed on unstained slides from 3 separate blocks; if >= 5% AR tumor staining is seen on >= 1 slide the tumor will be considered to be AR+
The patient must have at least 1 block of tissue available or 15 unstained slides at a minimum, for central pathology review and molecular profiling of the tissue sample
Patient must consent to provision of, and investigator(s) must confirm access to and agree to submit to the Canadian Cancer Trials Group (CCTG) Central Tumour Bank, a representative formalin fixed paraffin block of tumor tissue in order that the specific correlative marker assays described in the protocol may be conducted; where tissue exists but local center regulations prohibit submission of blocks of tumor tissue, the approval of the CCTG must be sought prior to randomization of the first patient to allow cores (two 2 mm cores of tumor from the block) and slides (20 x 5 micro thick unstained slides) of representative tumor tissue to be substituted; where tumor tissue is available, failure to submit any tissue samples will result in the patient being considered ineligible
A tumor block or 10 unstained slides must be available for determining EGFR mutational status; only those patients who have a mutation of the EGFR tyrosine kinase domain will be able to enroll in this study
Willing to provide tumor samples and / or slides
Availability at the site of tumor specimens in paraffin blocks (preferred) or 16 unstained slides, with an associated pathology report, prior to study entry
Tissue available for the required analyses (either clinical tissue block or slides and scrolls)
Pre-intervention biopsy tissue (most proximal to enrollment) with sufficient tumor tissue to cut 5-10 unstained slides confirmed to be available upon request
The pathology report and either (1) tissue (blocks or an unstained slides) or (2) a photomicrograph of the ER IHC slides from at least one site of metastatic disease and/or from primary breast cancer must be available for central review and analysis\r\n* NOTE: if photomicrographs are submitted, the submission of hematoxylin and eosin (H&E), PR and Ki67 IHCâ€™s, if performed, are also to be submitted
Patients must have available an archival paraffin tumor block sufficient to generate at least 10 unstained slides of 8 micron thickness; or, if a paraffin tumor block is unavailable, at least 10 unstained slides of 8 micron thickness
Availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of 1 cm^2 of tumor surface area from a tissue specimen that demonstrates pathological transformation to glioblastoma (WHO grade IV) or a progressive specimen that harbors one of the genetic alterations\r\n* If a tumor block cannot be submitted, then 20 unstained slides (preferably 10 slides from two different tumor blocks from the same surgery) from the tumor specimen must be submitted
Tumor tissue blocks or at least 20 unstained slides from a prior diagnosis will be requested; hematoxylin and eosin (H&E) to confirm diagnosis must be available; the 20 unstained slides is preferred, but not required
